Abstract Background Magnesium sulphate (MgSO 4) is the only treatment approved for fetal
neuroprotection. No information on its use is available in the absence of a national registry …

Background Intravenous administration of magnesium sulfate (MgSO4) to expectant
individuals before childbirth, has been evaluated to reduce the likelihood of mortality and …

In women at risk of early preterm imminent birth, from viability to 30 weeks of gestation, use
of MgSO4 for neuroprotection of the fetus is recommended. In pregnancies below 32–34 …

Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There
are some perceived differences in the international recommendations on the use …

Background Clinical practice guidelines recommend the use of antenatal magnesium
sulphate for fetal neuroprotection before preterm birth at< 30 weeks' gestation. Aims This …

Prevention of neurologic disability associated with preterm birth is one of the major
challenges in current perinatal medicine. Magnesium sulfate (MgSO4), the focus of this …

Background It is important to establish whether research recommendations regarding
magnesium sulphate for neuroprotection can be readily translated into clinical practice and …

ABSTRACT Background: Magnesium sulfate (MgSO4) can be used for the primary
prevention of cerebral palsy in preterm infants less than 37 weeks of gestational age. Aim …

Objective: To provide guidelines for the use of antenatal magnesium sulphate (MgSO4) for
fetal neuroprotection of the preterm infant. Options: Antenatal MgSO4 administration should …

Aims: We aimed to demonstrate the effect of magnesium sulfate for fetal neuroprotection on
maternal and neonatal outcomes of pregnants delivered before 32 weeks.